Support for Research, Patient Care in US 2021 Budget Wins Praise

Support for Research, Patient Care in US 2021 Budget Wins Praise
The Alzheimer’s Association and its advocacy affiliate, the Alzheimer’s Impact Movement (AIM), are lauding recent actions by lawmakers that will fund and advance multiple Alzheimer’s disease policies. The advancements are part of the $1.4 trillion government funding bill for the 2021 fiscal year that was passed by Congress on Dec. 21 and later signed into law by President Trump. The appropriations package includes a $300 million increase in Alzheimer’s and dementia research funding at the National Institutes of Health. It also earmarks $15 million to fund and implement the Centers for Disease Control and Prevention’s (CDC's) Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act. In addition, the package advances the Improving HOPE for Alzheimer’s Act. These elements were commended by the Alzheimer’s Association and by AIM, which works to advance and develop policies that increase investment in disease research and patient care and support. “Today’s agreement by congressional leaders reflects a broad, bipartisan commitment to accelerate the pace of progress toward breakthroughs in care, treatment, and prevention for Alzheimer’s and all other dementia,” Robert Egge, AIM executive director and Alzheimer’s Association chief public policy officer, said in a press release. “We are grateful to our longtime congressional champions for their steadfast commitment on behalf of the millions of Americans living with this devastating and fatal disease.” The organizations and their nationwide network of advocates worked behind the scenes for greater research support. A decade ago, when the National Alzheimer’s Project Act became law, the federal government’s investment in Alzheimer’s research totaled $448
Subscribe or to access all post and page content.